In patients with gout, a novel prediction tool that relies on weight and creatinine clearance successfully identified the dose of allopurinol required to achieve a serum urate (SU) level < 6 mg/dL in 77% of patients, and the remainder would likely have required only one dose adjustment to achieve the target.

Achieving target SU level is a challenge for both patients and physicians, according to Brian Coburn, MD, PhD, who presented the study at Gout Hyperuricemia and Crystal Associated Disease Network Annual Research Symposium (G-CAN) 2025. Physicians tend to default to a static low dose of allopurinol, and patients don’t always get their SU level measured. And if they do, physicians don’t necessarily alter the dose. “You iterate this over time, and we find that the large majority of patients fail to get to serum urate goal, leaving the monosodium urate crystals still intact and increasing the risk of gout flares and damage from gout,” Coburn said during his presentation.

Potential to Reduce Number of Steps to Reach Target SU Level

“So the question that I have from a behavioral standpoint is, do we need each of these required steps? Because when you think from a human factor or an engineering perspective, every action that’s required, every step, is a [potential] failure point in the system. So can we reduce these unnecessary steps?” said Coburn, who is a postdoctoral fellow of medicine at the Perelman School of Medicine, University of Pennsylvania, Philadelphia.

He searched the literature and discovered the Easy-Allo tool, which uses pharmacodynamics to predict a dose that can achieve SU level < 6 mg/dL and comes in two forms: Easy-Allo1 uses weight, creatinine clearance, and SU, while Easy-Allo2 uses just weight and creatinine clearance.

To validate the tools, Coburn tested them in a population drawn from the STOP Gout trial, which compared the efficacy of allopurinol and febuxostat in a treat-to-target strategy in patients with gout and found that allopurinol was noninferior to febuxostat. Patients could have been treated with allopurinol before the trial as long as the dose was ≤ 300 mg. It included 24 weeks of dose escalation followed by 12 weeks of dose modification in patients who had not reached the target SU level of < 6 mg/dL in patients without tophi, or < 5 mg/dL in patients with tophi.

Coburn’s team specifically looked at patients in the allopurinol group who completed at least 36 weeks of the study so that all dose adjustments had been completed. They excluded patients with tophi, and they also excluded patients who did not achieve SU goals. “We really wanted to focus on patients we knew could get to [the] serum urate goal, realizing that excluding those patients will change how you think about effectiveness a little bit,” Coburn said.

The population for validating Easy-Allo2 was 291 patients. For Easy-Allo1, they excluded patients who had a baseline SU value after previous treatment with allopurinol, leaving 181 patients for that validation. The original study emphasized recruitment of patients with stage III chronic kidney disease, such that 38% had it in the Easy-Allo2 cohort and 34% in the Easy-Allo1 cohort.

Coburn’s group found that 77% of patients in the Easy-Allo2 cohort would have achieved the target SU goal using the tool, and the remaining 23% would have needed further dose escalation. Easy-Allo2 predicted the required dose within 100 mg for 80% of patients. “This really does get you pretty close to the predicted dose, even if you have to dose escalate one more time, it’s just one more time,” Coburn said. Those patients who required dose escalation despite Easy-Allo2’s prediction were younger (60.6 vs 63.9 years; P = .04), had a higher baseline SU level (9.1 vs 8.3 mg/dL; P < .01), and a lower estimated glomerular filtration rate (61.6 vs 67.6 mL/min/1.73 m²; P = .02). Easy-Allo1 performed similarly, but those needing dose escalation were more likely to have a lower SU level (8.4 vs 8.9 mg/dL; P = .03).

Tool’s Potential Impact on Allopurinol Safety, Urate Testing

During the Q&A session after the presentation, an audience member asked if these prediction tools could affect safety. “The idea of getting to target more quickly — that sounds incredibly relevant. We have so much trouble with compliance. I guess if we do this, we’re not going to overshoot, but I think most of us tend to think if we go too quickly on the dose, we might invoke safety issues. Do you think that’s an issue that has to be addressed?” he asked.

In his response, Coburn acknowledged that it’s important to demonstrate safety. “I would also emphasize that I think that this would get people to goal more efficiently through better behaviors, but this does not have to be a rapid dose titration either. I think you can still avoid the initiation-type flares and the allopurinol hypersensitivity risks in those first 6 months,” he said.

Another questioner called Easy-Allo “a fantastic tool” but wondered whether genetic variability associated with metabolism could be incorporated into the model. Coburn said that some of the earlier iterations of the tool incorporated genetics, “but it was just a few genes, and not all of the ones that we’ve identified more recently. This really uses the variability over the entire population to average things, and I think through that you can get to strategies that are behaviorally useful without necessarily needing the genetics,” he said.

Lastly, a questioner raised a concern that a prediction model could reduce urate testing and potentially negatively affect treatment adherence. Coburn acknowledged being “a little bit worried about decreasing the engagement with the providers and the different steps” because of patients being more behaviorally attuned to things they are actively tracking and participating in. That sort of active participation may have contributed to positive outcomes seen in studies in which nurses or pharmacists actively managed allopurinol dose titration with patients. “I do think that is a challenge that we have to overcome with this sort of thing. With that said, I think this is a vast improvement over ignoring it completely, which is what we often see,” he said.

Coburn did not make any financial disclosures. This study received funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Jim Kling is a writer based in Bellingham, Washington.